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Exposure:activity ratio (EAR)An adverse outcome pathway (AOP) describes the causal linkage between initial molecular events and an
adverse outcome at individual or population levels. Whilst there has been considerable momentum in
AOP development, far less attention has been paid to how AOPs might be practically applied for different
regulatory purposes. This paper proposes a scientiﬁc conﬁdence framework (SCF) for evaluating and
applying a given AOP for different regulatory purposes ranging from prioritizing chemicals for further
evaluation, to hazard prediction, and ultimately, risk assessment. The framework is illustrated using three
different AOPs for several typical regulatory applications. The AOPs chosen are ones that have been
recently developed and/or published, namely those for estrogenic effects, skin sensitisation, and rodent
liver tumor promotion. The examples conﬁrm how critical the data-richness of an AOP is for driving
its practical application. In terms of performing risk assessment, human dosimetry methods are neces-
sary to inform meaningful comparisons with human exposures; dosimetry is applied to effect levels
based on non-testing approaches and in vitro data. Such a comparison is presented in the form of an expo-
sure:activity ratio (EAR) to interpret biological activity in the context of exposure and to provide a basis
for product stewardship and regulatory decision making.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Societal demands for safer and more sustainable chemical
products are stimulating changes in toxicity testing and assess-
ment frameworks. Chemical safety assessments are expected to
be conducted faster and with fewer animals, and at the same time,
the number of chemicals that require assessment is also rising with
the number of different regulatory programmes increasing world-
wide. These considerations have stimulated a shift in thinking
about how toxicity testing and their evaluations need be conduct-
ed in the future-moving away from extensive toxicity testing based
on phenotypic responses in animals towards pathway approaches
based on (quantitative) structure–activity relationships ((Q)SAR),
toxicokinetics, physiological mechanisms and dose-dependent bio-
logical changes underlying toxicity in exposed organisms. Since‘‘safety,’’ by deﬁnition, includes both the inherent hazards of the
substances that make up a product and exposures that occur as a
result of use of the product, improvements are needed in both
approaches for evaluating intrinsic hazards and approaches for
determining exposures. These visions were articulated to a large
extent in the 2007 NRC report ‘‘Toxicity Testing in the 21st Centu-
ry: A Vision and a Strategy’’ (NRC, 2007) and the 2012 NRC report
‘‘Exposure Science in the 21st Century: A Vision and A Strategy’’
(NRC, 2012; Cohen Hubal et al., 2010).
A move towards more mechanistically based risk assessments
implies with it the use of in vitro tests, including high throughput
and high content (HT/HC) screening methods, coupled with the
application of a range of computational methods for data analysis
and predictive modeling. Thus achieving the visions of Tox21 and
EXPO21 relies on 4 key components:
 The generation of in vitro data.
 The derivation of models from these biological activity assays
that predict downstream biological responses of toxicological
relevance.
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responses of toxicological relevance to exposures from uses of
chemical products.
 A tiered framework for proceeding to more complex assessment
procedures when greater precision is warranted to support a
speciﬁc regulatory or product stewardship decision.
A key, overarching component is a biological construct for
appropriate interpretation of these data so that prediction models
can guide regulatory uses and decision making. An adverse out-
come pathway (AOP) could serve as such a construct.
2. Adverse outcome pathway
An AOP is a sequence of events from the ﬁrst critical molecular
event (known as the molecular initiating event or MIE) to an in vivo
adverse outcome (AO) (Ankley et al., 2010). Although the molecu-
lar initiating event has been deﬁned as the ﬁrst key event (KE) in
the AOP causally linked to an adverse outcome, in practice the
MIE is being used to characterize the ﬁrst molecular interaction
which itself might not be causal. The term ‘‘initial molecular event’’
(IME) was coined by Patlewicz et al. (2013a) to replace the molecu-
lar initiating event in an effort to represent this important distinc-
tion1. Subsequent to the molecular initiating event, additional key
events will contribute to and culminate in the occurrence of the
adverse outcome. The Organization for Economic Co-operation and
Development (OECD) has developed guidance on developing and
assessing AOPs that is in alignment with guidance from the World
Health Organization (WHO), International Program on Chemical
Safety (WHO-IPCS) and ILSI Health and Environmental Science Insti-
tute (HESI) on mode of action (MoA), Human Relevance (HRF) and
Key Event Dose Response (KEDRF) (Julien et al., 2009; Meek et al.,
2003; Meek, 2008; Meek et al., 2014a,b; OECD, 2013).
OECD’s work programme for developing AOPs stemmed from
the desire to enhance read-across within chemical categories. AOPs
should thus facilitate the transition from categories that have been
largely structurally based to categories that are informed by the
inclusion of additional biological information (van Leeuwen et al.,
2009). In 2010, the OECD held a workshop entitled ‘‘Using
Mechanistic Information in Forming Chemical Categories.’’ This
workshop discussed the types of activities that could form the
basis of an OECD AOP work programme including the development
of a library of AOPs and MIEs which could subsequently be includ-
ed in the OECD QSAR Toolbox (OECD, 2011). A complementary dri-
ver was the 7th Amendment to the Cosmetics Directive which
established a ban on animal testing for repeated dose toxicity end-
points for cosmetics by 2013 (EC, 2009; Hartung et al., 2011).
Indeed an ongoing joint research effort between Cosmetics Europe
and the European Commission known as SEURAT-1 is investigating
approaches to replace the types of repeated dose toxicity testing
that would be necessary to assure the safety of cosmetic sub-
stances by exploiting an AOP framework (http://www.seurat-1.
eu/).
Whilst there is a wealth of activity on the development of AOPs
in particular within the OECD programme, far less attention has
been placed on their evaluation and practical application in a
regulatory context. The purpose of this paper is to propose a scien-
tiﬁc conﬁdence framework (SCF) to outline the types of consid-
erations pertinent when applying and evaluating AOPs for
different regulatory purposes and to highlight its utility with a
few illustrative examples. The SCF incorporates established think-
ing regarding Mode of Action (MoA), the notion of ‘‘ﬁt-for-purpose’’1 Drewe et al. (2014) coined the term pre-MIE as an alternative to IME to make the
same distinction. This was in an effort to ensure that MIEs that were not truly causally
linked were not being used as direct predictors of the adverse outcome.as a necessary aspect of problem formulation, and the need to con-
sider human dosimetry (Becker et al., 2012, 2014b,c).3. Challenges in applying AOPs in regulatory decision making: a
framework to document scientiﬁc conﬁdence
The OECD AOP work programme foresees AOPs as addressing
several different regulatory purposes. These include (1) develop-
ment of chemical categories based on biological responses (2)
informing test method reﬁnement/development and (3) develop-
ing integrated approaches to testing and assessment (IATA) for
hazard and risk assessment. Although not explicitly stated in the
OECD work programme, AOPs can also be used for prioritization
purposes, which may be viewed as a distinct application stemming
from chemical categorization based on biological responses. In
addition, an AOP can be used as the central organizing conceptual
approach for a chemical risk assessment, in a manner analogous to
the use of MoA in the ILSI KEDRF and HESI Q-KEDRF (Julien et al.,
2009; Simon et al., 2014).
The current OECD AOP work programme falls under the direc-
tion of the Extended Advisory Group for Molecular Screening and
Toxicogenomics (EAGMST), and is focused on the development of
AOPs, associated guidance and knowledge management tools such
as the AOP Wiki. Although there is a workﬂow described to out-
line the steps of AOP development, the endorsement and regula-
tory application, as noted by Vinken (2013), has not yet been
considered in any great detail by the OECD. In an idealized case,
an AOP would include a description of all key events, delineation
of methods which can be used to measure each key event,
descriptions of each key event relationship (KER), and quantitative
models for each KER to permit statistical prediction of a down-
stream key event from an upstream key event. If all of this infor-
mation were available, quantitative predictions of the adverse
outcome (AO) could be made from an upstream key event. How-
ever, for almost all AOPs, our current state of understanding does
not allow for a quantitative prediction of a downstream key event
or the ultimate adverse outcome from an upstream key event.
Typically, quantitative prediction models are lacking, and thus
predicting quantitative hazards falls short of achieving the desired
degree of scientiﬁc conﬁdence. Therefore, the use of AOPs to
quantitatively predict human toxicity or risks may not become
routine for some time to come. Nonetheless, depending upon
the degree of understanding, AOPs can still be practically used
in a number of ways for regulatory purposes. The extent to which
an AOP can be used in any of the applications delineated above
will depend on the maturity or completeness of the AOP itself.
The application of a given AOP to a speciﬁc regulatory challenge
will depend in a large part on how the scientiﬁc basis of the
AOP has been justiﬁed and documented.
Cox et al. (2014) put forward a scientiﬁc conﬁdence framework
designed to aid in the development, evaluation and communica-
tion of the scientiﬁc conﬁdence in Tox21 assays and their predic-
tion models. Speciﬁcally the framework was designed as a means
of documenting the performance and robustness of assays and
their prediction models within the context of a biological pathway
that culminated in an adverse effect (i.e., an AOP) and was aimed at
a given regulatory purpose, whether it be for priority setting, read-
across, screening level hazard identiﬁcation, etc. The framework
was derived using the OECD QSAR validation principles (OECD,
2004) and the Institute of Medicine (IOM) biomarkers guidance
(IOM, 2010). It is composed of three inter-related core elements,
(1) analytical validation, (2) qualiﬁcation and (3) utilization which
can be readily adapted for AOPs. These three core elements have
been integrated in an extended scientiﬁc conﬁdence framework
for AOPs in a stepwise manner (Table 1).
Table 1
Scientiﬁc conﬁdence framework adapted for AOPs.
Step Scientiﬁc
conﬁdence element
Description
1 AOP development Develop the AOP
2 Mapping assays Develop new (or map existing) speciﬁc assays
to demonstrate key events within the AOP
3 Analytical
validation of assays
Conduct (or document) analytical validation of
each assay. (Assessment of the biological basis
and analytical performance of assays. Each
assay (including HT/HC screening assays)
should map to a deﬁned mechanistic endpoint
(e.g., the intermediate or key event in the mode
of action or AOP). A deﬁned chemical domain of
applicability and documentation of assay
performance characteristics (reliability,
sensitivity, and speciﬁcity) and transparent data
sets (to enable independent veriﬁcation) should
be readily available)
4 Prediction model
development
Develop new (or map existing) models that
predict a speciﬁc key event from one or more
precursor key events. (The input data for the
prediction models comes from the assays
described in Steps 2 and 3 above)
5 Qualiﬁcation of
prediction models
Conduct (or document) qualiﬁcation of the
prediction models. (Assessment of the
prediction model derived from the (HT/HC)
screening assays. A deﬁned algorithm for each
prediction model is needed to ensure
transparency. Appropriate measures of
goodness-of-ﬁt, robustness and predictivity of
the prediction model need to be presented.
Some prediction models may be quantitative,
others may be qualitative. Known limitations of
each prediction model should also be
summarized. Prediction models should be
characterized in sufﬁcient detail to facilitate
review, reconstruction and independent
veriﬁcation of results)
6 Utilization for
speciﬁc purposes
Utilization: deﬁning and documenting where
there is sufﬁcient scientiﬁc conﬁdence to use
one or more AOP-based prediction models for a
speciﬁc purpose (e.g., priority-setting, chemical
category formation, integrated testing
strategies (ITS), predicting in vivo responses,
etc.)
7 Regulatory
acceptance
For regulatory acceptance and use, processes
need to be agreed upon and utilized to ensure
robust and transparent review and
determination of ﬁt-for-purpose uses of AOPs.
This should include dissemination of all
necessary datasets, model parameters,
algorithms, etc., to enable stakeholder review
and comment, fully independent veriﬁcation
and independent scientiﬁc peer review. Whilst
these processes have yet to be deﬁned globally,
in time, these should evolve to enable credible
and transparent use of AOPs with sufﬁcient
scientiﬁc conﬁdence by all stakeholders
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the degree of conﬁdence is in predicting the adverse outcome
within the AOP and whether this is sufﬁcient to support the use
of the AOP for a given purpose e.g., prioritization; read-across; haz-
ard identiﬁcation; etc.?’’ In order to arrive at such a conﬁdence
determination for an AOP, the OECD AOP Handbook guidance on
conducting a Weight of Evidence (WoE) evaluation on an AOP
can be used (published in September 2014 on the AOP Wiki). The
procedures in this guidance entail completing a template, using
evolved Bradford Hill (BH) considerations, in which each key event
and key event relationship within the AOP are evaluated and
qualitatively scored as High (H). Moderate (M) or Low (L). The
WoE determinations help address the degree of scientiﬁc conﬁ-
dence for using the AOP for a deﬁned purpose. In other words,the conﬁdence underpinning the use of an AOP for a speciﬁc appli-
cation will be commensurate with the ability of the user to provide
sufﬁcient scientiﬁc justiﬁcation that the knowledge of key events
and their relationships is such that a qualiﬁed and appropriately
knowledgeable scientiﬁc reviewer would concur that the deﬁned
application proposed is scientiﬁcally supported. Thus, the users’
justiﬁcation should include a rationale explaining whether a quan-
titative use of an AOP is justiﬁed, or if not, whether a qualitative use
is supported.
If a speciﬁc key event or key event relationship is judged, in the
WoE determination, to be weak, then one is likely to have low con-
ﬁdence proceeding along the AOP pathway beyond that key event
or key event relationship to predict subsequent key events or the
adverse outcome. The weak level of conﬁdence represents a break-
point in the causal pathway. The most inﬂuential consideration in
assessing the WoE in the overall AOP for regulatory application is
the biological plausibility of each of the key event relationships
in the AOP. The essentiality of the key events and the extent of
empirical support for each key event relationship are secondary
considerations.
Per the WoE determinations in Table 2, one would have insufﬁ-
cient scientiﬁc conﬁdence in quantitatively predicting KE2 from
either the IME or KE1. Thus, one would not be able to proceed past
this breakpoint in the causal pathway to quantitatively predict KE3
or the AO from the IME or KE1 although, qualitative predictions of
the AO may be possible.
In terms of application of an AOP for priority setting purposes,
where the decision is to identify substances that will undergo a
more extensive evaluation using more complex and precise test
methods, perhaps all that is needed is solid scientiﬁc conﬁdence
in the biological plausibility of the AOP and high conﬁdence in
the assay(s) that measure the IME. Results of such assays that mea-
sure activities of substances indicative of the IME or KE1 could be
used quantitatively for prioritization purposes, for read-across or
for IATA development. For IATA purposes (which are discussed in
more detail in Section 3.4), one may be able to use the AOP as a
decision tree, in which assessment proceeds sequentially starting
with the IME. If a positive response is seen, the key event outcome
of the substance is then predicted using the KER. If there is a break-
point in the AOP causal chain, then the IATA scope will be limited
and new data would need to be generated.
From a reviewer’s perspective, it is insufﬁcient for an applica-
tion of an AOP to simply document its use; one needs to indicate
the rationale for the speciﬁc use and the scientiﬁc support under-
pinning such a use. Limitations of use should also be noted. Since
experience in developing, applying and reviewing AOPs is current-
ly very limited, it is important to use the OECD AOP WoE template
procedures to document one’s understanding of the WoE of the
AOP and each key event and key event relationship. These WoE
determinations and subsequent use of these determinations for
communicating the scientiﬁc foundation supporting use of an
AOP for a particular application will form the basis for expanding
the knowledgebase of AOPs. This will foster scientiﬁc discussions
and consensus will emerge as to which applications are scien-
tiﬁcally sound and which are more limited or speculative.
Thus the scientiﬁc conﬁdence framework (SCF) proposed here
complements the OECD guidance on AOPs. Whilst the OECD guid-
ance describes the approach to develop an AOP including the key
events and key event relationships, it is largely silent on document-
ing conﬁdence in (1) the analytical methods used to measure key
events, (2) the prediction models (which are in essence, the key
event relationships) and (3) the rationale and justiﬁcation for deci-
sions to use (or not use) an AOP for a given regulatory application. It
is recognized that different regulatory decisions will require
differing levels of scientiﬁc conﬁdence; which will in turn impact
the amount and type of data required in the development and
Table 2
WoE determinations for a hypothetical AOP.
Key Event / 
Key Event 
Relationship
IME KER1 KE1 KER2 KE2 KER3 KE3 KER4 AO
WoE High High High Low Moderate Moderate High High High
High
Low
High
Confidence in quantitatively 
predicting KE1 from IME1 & 
KER1
Confidence in quantitatively 
predicting KE2 from KE1 & 
KER2
Confidence in quantitatively 
predicting KE3 from KE2 & KER3 Moderate
Confidence in quantitatively 
predicting AO from KE3 & 
KER4
Notes: IME – initial molecular event, KE – key event, KER – key event relationship, AO – adverse outcome, WoE – weight of evidence.
Fig. 1. Tradeoff between the conﬁdence in the use of an AOP to quantitatively
predict the adverse outcome (AO) and the associated model uncertainties depend-
ing on the type of regulatory decision.
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dence needed to make a quantitative AO prediction and the under-
lying uncertainty is represented conceptually (Fig. 1).
In the following sections, we aim to highlight the utility of the
scientiﬁc conﬁdence framework for several regulatory purposes
using three AOPs, namely those for estrogen mediated activity,
skin sensitisation, and sustained AHR activation leading to rodent
liver tumors. These AOPs are referenced in the AOP Wiki which
was made public in September (see https://aopkb.org/aopwiki/in-
dex.php/Main_Page). The Wiki contains a reasonable though not
exhaustive listing of AOPs currently under development. It is
important to note that these illustrative examples are intended
to highlight some of the regulatory purposes that could be poten-
tially considered for these speciﬁc AOPs. We have not performed a
detailed evaluation of each AOP using the framework proposed nor
considered the extent to which these AOPs could address other
purposes. Some of the AOPs herein may serve other purposes
beyond what we have described. We also have not addressed the
issue of how substances could be practically assessed by exploiting
information arising from multiple AOPs. That is beyond the scope
of this manuscript. We do however discuss aspects of dosimetry
in how data generated from early events in AOPs need to be inter-
preted in the appropriate context for risk assessment purposes.3.1. Prioritization
In prioritization, substances are screened to identify those with
measureable biological activity, and those judged in such screensto be positive could then be ranked ordered from least potent to
most potent and weighted as to their margin of exposure (MOE),
with the most potent and/or smallest MOE having the highest pri-
ority to undergo more detailed evaluation or testing. Typically,
applying an AOP for prioritization would entail using a speciﬁc
assay, or a battery of assays, and a prediction model which relates
the observed results to a biological response that is a given key
event in an AOP. As a minimum, the biological basis of the assay
or assays should be understood to facilitate interpretation in the
context of a pathway. For priority setting, the most probable sce-
nario is to use assays that measure the initial molecular event.
The prediction model could be as simple and straightforward as
‘‘positive responses in these assays correspond to a critical early
(or initial) key event in the pathway leading to the adverse out-
come.’’ For priority setting purposes, it is not necessary to have a
prediction model that quantitatively relates responses in an early
key event to the probability of development of the adverse out-
come. Whilst the assay(s) should be anchored to a key event that
is relevant for the adverse outcome of concern, a full understand-
ing of the quantitative dose–response of each key event or quanti-
tative relationships between all of the key events in the AOP is not
needed for this type of application. Of course, it is recognized that
having dose–response information would allow for rank ordering
of chemicals from lowest to highest priority.
3.1.1. Case study 1: endocrine activity AOP leading to reproductive
dysfunction
A prioritization application is discussed in Table 3 where the
focus is on using biological activity indicative of an early key event,
in this case from estrogen receptor (ER) binding and transactiva-
tion assays, as the basis for setting priorities. Speciﬁcally estrogen
receptor binding (ERBA) and transactivation assays (ERTA) are tak-
en as early key events in the AOP of adverse human health effects
associated with exposure to estrogenic agents. Fig. 2a depicts Step
2 (mapping assays to the AOP KEs) and Step 3 (analytical validation
of assays). Fig. 2b illustrates prediction model development (Step
4) and qualiﬁcation (Step 5). The cross validation AOP prediction
model uses measurements of molecular interactions (ER binding)
and cellular responses (ER-mediated transcription) to predict
in vivo uterotrophic responses (Rotroff et al., 2013; Cox et al.,
2014). In this case example, the positive and negative predictivity
(balanced accuracy) of the model was shown to be 85%. As noted in
Cox et al., 2014, Step 6 (utilization) requires addressing such ques-
tions as: what is the acceptable range of predictivity of the model
Table 3
Use of the scientiﬁc conﬁdence framework for an endocrine activity AOP within the
context of prioritization.
Step Scientiﬁc conﬁdence
element
Action required
1 AOP development For the estrogen-mediated adverse outcome
pathway for human health evaluation, link the
KEs commencing with molecular interactions,
proceeding through cellular and organ
responses and culminating with adverse
effects
2 Mapping assays Identify assays that are used in the Endocrine
Disruption Screening Programme (EDSP) (see
http://www.epa.gov/endo/) to evaluate each
of the KEs in the AOP
3 Analytical validation For the speciﬁc ERBA and ERTA assays,
document performance. Such as the studies
published by EPA as part of their validation
effort for the EDSP (see http://www.epa.gov/
endo/)
4 Prediction model
development
For example, use of ToxCast™ ERBA and ERTA
assays to predict the in vivo EDSP Tier 1
uterotrophic response per Rotroff et al. (2013)
and Cox et al. (2014)
5 Qualiﬁcation of the
prediction models
Document the performance of the model(s)
that predict KEdownstream from KEupstream. For
example, per Cox et al. (2014), evaluation of
the positive and negative predictivity of the
model developed using ToxCast™ ERBA and
ERTA assays to predict the in vivo EDSP Tier 1
uterotrophic response
6 Utilization for
speciﬁc purposes
Describe the WoE of the speciﬁc KEs of
estrogen receptor binding and gene
expression in the AOP and the rationale
supporting use for setting priorities for EDSP
screening. Use the WoE guidance in the OECD
AOP Handbook (OECD, 2014a), to document
evaluation of estrogen receptor binding and
gene expression KEs and KERs for biological
plausibility, essentiality, empirical evidence
and uncertainties. Describe the level of conﬁ-
dence arrived at in the context of speciﬁc
applications. Address questions such as: what
is the acceptable range of predictivity of the
model for prioritizing substances for EDSP?
For bypassing certain receptor-mediated EDSP
ER-based Tier 1 assays? For bypassing the
in vivo EDSP uterotrophic assay?
7 Regulatory
acceptance
Make available in publications, or in
supplemental material (or by other means)
the datasets, model parameters, algorithms
and utilization rationales, etc. (for discussion,
see Cox et al., 2014 as an example)
EDSP = endocrine disruption screening programme, ERBA = estrogen receptor
binding assay, ERTA = estrogen receptor transactivation assay, KE = key event,
KER = key event relationship.
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tor-mediated EDSP ER-based Tier 1 assays? For bypassing the
in vivo uterotrophic assay? It has been shown that the priority
setting approach can be improved by integrating exposure infor-
mation with biological activity (Wambaugh et al., 2013). Using
the example outlined in Table 3, Becker et al. (2014b,c) have shown
that calculating exposure:activity ratios (EARs) for estrogenic che-
micals and comparing these to the EAR for the phytoestrogen
genistein can provide a reﬁned context for priority setting for
regulatory decision making.
3.2. Chemical categories and associated read-across
A chemical category is deﬁned as a group of chemicals whose
physicochemical and human health and/or ecotoxicological
properties and/or environmental fate properties are likely to be
similar or follow a regular pattern, usually as a result of structuralsimilarity (OECD, 2007; ECHA, 2008). The similarities may be based
on the following:
 A common functional group (e.g., aldehyde, epoxide, ester,
speciﬁc metal ion).
 Common constituents or chemical classes, similar carbon range
numbers.
 An incremental and constant change across the category (e.g., a
chain-length category).
 The likelihood of common precursors and/or breakdown prod-
ucts, via physical or biological processes, which result in struc-
turally similar chemicals (e.g., the metabolic pathway approach
of examining related chemicals such as acid/ester/salt).
These ‘‘similarity rationales’’ may be considered as representing
the overarching hypothesis for grouping two or more chemicals
together as part of an analogue or category approach. The next step
requires the grouping to be justiﬁed on the basis of general consid-
erations such as bioavailability, reactivity, and metabolism, which
themselves are informed through non-testing approaches such as
(Quantitative) Structure Activity Relationships ((Q)SARs) as well
as experimental test data. Once the category has been nominally
established, aspects pertinent to different apical endpoints are
then considered to determine the scope of the category for ﬁlling
data gaps for speciﬁc endpoints. For example, a category or ana-
logue approach derived on the basis of a metabolic pathway
between a parent and its primary metabolite may be applicable
to all mammalian systemic endpoints but will not necessarily be
applicable to local effects such as irritation or indeed for environ-
mental fate properties (OECD, 2007; Patlewicz et al., 2013b).
Populating the data matrix (a matrix of category members vs.
available information per endpoint) assists in this evaluation to
identify what consistency exists across the category members for
different hazard endpoints. Data gap ﬁlling approaches such as
read-across or trend analysis can then be used to predict the effects
of untested chemicals (OECD, 2007; ECETOC, 2012). With the
increase of chemical regulatory programmes such as REACH, the
desire to exploit read-across approaches as a means of addressing
data gaps has increased but acceptance has been somewhat lacking
in practice, especially for complex endpoints such as repeated dose
toxicity (Ball et al., 2014). This may be in part due to the absence of
a systematic framework to identify and address read-across uncer-
tainties (Patlewicz et al., 2014a). Indeed this might also be due to
the fact that read-across has been traditionally anchored with che-
mical structural similarity without a meaningful way of integrating
biological similarity. Exploiting information from AOPs to enhance
read-across could help resolve some of these uncertainties as
approaches to characterize the different key events would provide
a means of demonstrating biological similarity (Patlewicz et al.,
2013b, 2014a; Ball et al., 2014). If an AOP were available for such
a complex endpoint, read-across predictions for an in vivo endpoint
could be potentially substantiated by generating in chemico or
in vitro data to characterize the molecular initiating event and/or
other downstream key events as necessary. Thus in terms of the
information considerations, analytical validation of the assays
characterizing speciﬁc key events and qualiﬁcation of their predic-
tion models would ideally be required to justify the similarity
rationale as well as the subsequent read-across prediction within
a chemical category, whereas a full quantitative understanding of
the key event relationships to predict the adverse outcome would
not be necessary. A discussion on how AOPs can be used in the for-
mation of categories and associated read-across is also described in
the recently revised OECD grouping guidance (OECD, 2014a). As
part of the OECD AOP work programme, AOPs are envisaged to
be implemented into the OECD QSAR Toolbox to facilitate forma-
tion of chemical categories and their associated read-across.
Fig. 2a. Mapping relevant assays that anchor to key events in the AOP for endocrine activity, speciﬁcally the estrogen receptor binding (ERBA) and transactivation assays
(ERTA) as early key events, the in vivo uterotrophic assay as an intermediate event and the 2 generational reproductive toxicity to characterize the adverse outcome of
reproductive dysfunction.
Fig. 2b. Characterizing the performance of a prediction model that relies on ER binding and ER mediated transcription to predict in vivo uterotrophic responses. Notes: EDSP –
EPA’s endocrine disruptor screening program.
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categorization and read-across
This case study was chosen for a number of reasons. Skin sensi-
tisation is an endpoint that has been well studied over many years
and is sufﬁciently simple to illustrate the AOP construct. There is a
wealth of data that has been already generated in alternative test
methods that lend themselves to the development of structural
proﬁlers that would be required for the AOP to be incorporated
into the OECD Toolbox. The OECD Toolbox proﬁlers encode rele-
vant structural characteristics and/or potential modes of action
into rules. The structure–activity information may be based around
chemistry principles and relevant to many endpoints or related
towards particular toxicity endpoints. Given that all the key events
leading up to the adverse outcome are characterized and well sup-
ported experimentally, the AOP for skin sensitisation could be con-
sidered mature, though semi-quantitative AOP in nature. In termsof the SCF, the richness of this AOP renders it potentially applicable
for different regulatory purposes including read-across (Table 4).
As noted in Table 4, the MIE is deﬁned as the covalent interac-
tion of the electrophilic test substance and/or its metabolite(s)
with nucleophilic skin proteins and the AO as allergic contact der-
matitis (OECD, 2012a,b; Landsteiner and Jacobs, 1936; Godfrey and
Baer, 1971; Dupuis and Benezra, 1982). Numerous efforts have
focused on identifying the electrophilic features in chemicals and
representing these as structural alerts. Other strategies have
involved developing QSAR approaches, for example the hybrid
expert system TIMES-SS which incorporates structure–toxicity
and structure-metabolism rules, some of which are underpinned
with 3D QSARs, to provide a semi quantitative measure of skin sen-
sitisation potency (Patlewicz et al., 2014b). Reaction mechanistic
domains based on organic chemistry principles have also been for-
mulated to facilitate the grouping of chemicals for the purposes of
Table 4
Testing/non-testing approaches for key events within the skin sensitization AOP.
Key event number Key event Level of biological
organization
Testing/non-testing approaches
Key event (KE) 1
(MIE)
Covalent binding between electrophile and
skin protein
Molecular level DRPA (Gerberick et al., 2004, 2007), GSH (Schultz et al., 2005),
QSARs/read-across
KE2 Activation of inﬂammatory cytokines Cellular response KeratinoSens™ (Emter et al., 2010, 2013), read-across
KE3 Maturation and mobilization of dendritic cells Cellular response MUSST (Python et al., 2007), h-CLAT, read-across
KE4 T-cell proliferation Organ response LLNA (OECD TG 429), QMM, read-across
Adverse outcome
(AO)
Allergic contact dermatitis Organism response GPMT (OECD TG 406), HRIPT
DRPA = direct reactivity peptide assay, GSH = glutathione depletion assay; MUSST = myeloid U937 skin sensitization test; h-CLAT = human cell line activation test;
LLNA = local lymph node assay; QMM = quantitative mechanistic model; GPMT = guinea pig maximization test; HRIPT = human repeat insult patch test.
Table 5
Use of the scientiﬁc conﬁdence framework within the context of employing the AOP
for skin sensitization for chemical categorization and read-across.
Step Scientiﬁc conﬁdence
element
Action required
1 AOP development Semi quantitative AOP has been published by
OECD in 2012
2 Mapping assays Non-testing approaches and assays for several
of the KEs have been mapped to the AOP, e.g.,
KeratinoSens™, DPRA, h-CLAT, LLNA, GPMT
(see Table 4)
3 Analytical validation KeratinoSens™, DRPA and h-CLAT have been
formally validated by ECVAM. DRPA and
KeratinoSens™ and h-CLAT exist as draft
OECD test guidelines. The LLNA (OECD TG
429) has been extensively validated with
respect to guinea pig and human data. For
chemical categorization/read-across purposes,
extracting the structural features of chemicals
experimentally measured in these assays
provides a measure of the structural domain
of applicability
4 Prediction model
development
Prediction models to interpret the outcomes
of each of the assays and how these relate to
the AOP can be found in the primary
references of the speciﬁc test protocols
5 Qualiﬁcation of the
prediction models
Assessment of some of the prediction models
include Reisinger et al. (2014), Urbisch et al.
(2014), van der Veen et al. (2014)
6 Utilization for
speciﬁc purposes
The similarity rationale to justify an initial
category can be based on the reaction
chemical domains (Aptula et al., 2005) and/or
structural alerts. To substantiate the rationale
and to perform a read-across prediction,
reactivity and hydrophobicity information
would be needed. The former can be derived
from the DRPA or other kinetic studies e.g.,
GSH. QSAR approaches may also be useful as
part of the WoE approach. If the read-across is
being used for hazard characterization or risk
assessment, and/or if the reactivity informa-
tion is not sufﬁcient, other KE data may be
generated from corresponding assays to in-
crease conﬁdence in the outcome
7 Regulatory
acceptance
Notable datasets of the available assays
include Natsch et al. (2013). Other datasets
have been made available within the OECD
Toolbox
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(Aptula et al., 2005). Appropriate measures of reactivity and/or
hydrophobicity can be determined to estimate a measure of
sensitisation potency either through using a derived QMM or by
read-across for ‘‘similar’’ chemicals as determined by their reaction
domain (Roberts et al., 2008). In terms of the experimental meth-
ods that exist to measure reactivity, the direct peptide reactivity
assay (DPRA) (Gerberick et al., 2004) or the glutathione depletion
assay (GSH), (Schultz et al., 2005) are examples. The DRPA provides
a measure of inherent reactivity but not in a form that can be
linked back to a rate constant, which itself has been shown to be
predictive of T-cell proliferation as measured in the LLNA and rep-
resented as KE4 in the AOP (Roberts et al., 2008; Roberts and
Patlewicz, 2014). This is perhaps why the percentage of peptide
depletion over a 24 h period as measured in the DRPA gives rise
to a weak quantitative relationship with the EC3 from the LLNA,
i.e., the DPRA results do not accurately represent the MIE quantita-
tively (Roberts and Patlewicz, 2014). Several of the experimental
test systems cited (DRPA, KeratinoSens™, h-CLAT) have been
validated by ECVAM and of these two, namely the KeratinoSens™
and the DRPA, are now OECD test guidelines (OECD, 2015a,b). The
application of the scientiﬁc conﬁdence framework to evaluate the
suitability of the skin sensitisation AOP and associated assays for
application in read-across is examined (Table 5).
In brief, the similarity rationale to group chemicals to evaluate
their sensitising ability is ideally based on mechanistic reaction
domains or structural alerts encoding electrophilic features. To
substantiate the hypothesis, information characterizing the MIE
would need to be generated. This could take the form of the DRPA
or preferably other reactivity experimental studies which provide
kinetic information. Information from QSARs can be helpful as
additional evidence as part of a WoE approach. Reactivity informa-
tion should be sufﬁcient to substantiate the similarity on account
of the strong evidence supporting the essentiality of this MIE and
due to the many QMM/QSAR studies that have related the MIE to
the EC3 value (i.e., the effective concentration at a simulation index
of 3) as measured in the LLNA. For a read-across prediction, the
level of conﬁdence will be both context- and chemical-speciﬁc.
Chemical-speciﬁc since, depending on the reaction domain, infor-
mation on hydrophobicity as modeled by LogKow, in conjunction
with reactivity data, will be needed to justify the prediction of sen-
sitisation potential and/or potency. Context-dependent since the
typical assays currently available to characterize the KEs are only
able to provide information to discriminate sensitisers from non-
sensitisers. Depending on these 2 factors, information from other
downstream KEs such as data from the h-CLAT or KeratinoSens™
may be needed to increase the conﬁdence of the read-across pre-
diction for sensitisation potential. Alternatively existing in vivo
data for one or more of the category members could provide sufﬁ-
cient information to support a read-across prediction of potency.
The integration of these different sources of information starts totransition into the area of IATA which is discussed in more detail
in Section 3.4.3.2.2. Case study 3: AHR rodent liver tumor AOP
The MoA for rodent liver tumor promotion by the aryl hydrocar-
bon receptor (AHR) presents challenges for chemical categorization
and associated read-across even though it is one of the more
experimentally rich MoAs (Budinsky et al., 2014) (see Table 6).
Table 6
AOP for the sustained AHR activation leading to rodent liver tumors.
Key event number Key event Level of biological
organization
Testing/non-testing approaches
Initial molecular
event (IME)
Short-term AHR activation Molecular level Endogenous gene expression, reporter gene expression,
receptor binding assay, (Q)SAR/read-across
Key event (KE) 1
(MIE)
Sustained AHR activation Molecular level Endogenous gene expression from sub-chronic in vivo
studiesa
KE2 Changes in apoptosis, proliferation and cellular
homeostasis
Cellular response In vitro primary parenchymal and non-parenchymal cell
studies; in vivo histopathology and immunohistochemical
staining from in vivo repeated dose studies and initiation-
promotion studies
In vivo (initiation-promotion) and in vitro primary
hepatocyte evidence
KE3 Hepatopathy constellation of histopathological changes,
hyperplasia
Organ response In vitro primary liver cell studies; in vivo histopathology and
immunohistochemical staining from in vivo repeated dose
studies"bBrdU-labeling, oval cells and bile duct hyperplasia
Adverse outcome
(AO)
Liver tumors Organism response Rodent cancer bioassay
"Hepatocellular adenomas, cholangiomas and
cholangiolar carcinomas
a Phenotypic anchoring of genomic changes, pathways and networks to KE2 and KE3 are current data gaps requiring a better understanding of subchronic and chronic
changes in transcription, that are direct or indirect outcomes of sustained AHR activation, in both parenchymal and non-parenchymal cells.
b BrdU = 5-bromo-2-deoxyuridine.
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all AHR ligands are likely to be rodent liver tumor promoters, espe-
cially the naturally occurring short-acting, readily metabolized
ligands of lower potency (NTP, 2014). In contrast, the potent and
persistent co-planar AHR ligands represented by speciﬁc polychlo-
rinated dibenzo-p-dioxins, furans and PCBs are readily recognized
for their rodent liver tumor promotion hazard based on their abil-
ity of inducing sustained AHR activation and the MIE (Zhao et al.,
2008; Petkov et al., 2010; Cao et al., 2013). The challenge for
categorization stems from realizing that the initial molecular inter-
action, e.g., AHR binding and activation may not be sufﬁcient to
link early AHR activation-induced changes to the AO of liver
tumors. Indeed a diverse range of naturally occurring and synthetic
ligands bind to and activate the AHR to alter the expression of hun-
dreds of genes, some of which presumably promote the clonal
expansion of altered hepatic foci (reviewed in Denison et al.,
2011; Nguyen and Bradﬁeld, 2008; Forgac et al., 2012; Yao et al.,
2012; Boverhof et al., 2006; Rowlands et al., 2011; Fletcher et al.,
2005). However, it is unlikely that the large number of naturally
occurring or short-acting AHR ligands act as tumor promoters. Fur-
thermore, AHR activation has been reported to inhibit apoptosis
within altered hepatic foci providing the initiated cells an opportu-
nity to replicate and acquire additional mutations (Chopra and
Schrenk, 2011). AHR activation affects both parenchymal and
non-parenchymal cells, in a zonal-dependent manner, with
involvement in AHR-mediated liver tumor promotion. The KE
information points to an important role for abnormal hepatic stem
cell growth and differentiation, e.g., biliary ﬁbrosis, oval cell hyper-
plasia (Hailey et al., 2005; Sheikh-Bahaei et al., 2010; Andersen
et al., 1997; Chang et al., 2005). In addition to the indirect stimula-
tion of clonal expansion produced by intrafocal apoptosis inhibi-
tion, sustained AHR activation and its accompanying
histopathological changes produce a direct proliferative environ-
ment to stimulate the clonal expansion of altered focal growth.
These complex KE aspects of this AOP illustrate the challenges with
prioritization and categorization of a substance based on limited
data such as AHR binding and/or activation. The applicability of
read-across for prioritizing and/or categorizing AHR ligands is
largely limited to the straightforward examples of obvious, copla-
nar halogenated polyaromatic hydrocarbons. For example, a recent
NTP cancer bioassay showed that indole-3-carbinol, a naturally
occurring AHR ligand, failed to produce liver tumors as well as
the classic hepatopathy ﬁndings closely linked to TCDD-inducedliver tumors in female Sprague Dawley rats (NTP, 2014; Hailey
et al., 2005).
3.3. Informing test method reﬁnement and/or development
AOPs as noted by the OECD, can provide information relevant to
test method development or reﬁnement, e.g., the need for develop-
ment of a new method, or reﬁnement of an existing method, to
measure a speciﬁc key event. The need for a new test method or
improvement of an existing test method may arise when an AOP
developer attempts to map existing speciﬁc assays to each key
event within the AOP. Alternatively the need may arise when a
developer or user evaluates the performance of an assay used to
measure a key event. The need for new methods or reﬁnements
may arise when the performance of a key event relationship, or
prediction model, based on an existing assay falls short because
of issues with the key event measurement method e.g., technical
limitations such as lack of metabolic competence or water solubi-
lity limits. In any of these cases, since the conﬁdence in the AOP
hinges upon the scientiﬁc robustness in the methods used to mea-
sure key events, application of an AOP may be limited until such
time as one or more test methods are improved. Drawing again
from the EDSP, as an example, consider the in vitro ToxCast™ test
methods used to evaluate thyroid effects. Rotroff et al. (2013)
demonstrated that the ToxCast™ assays could not be used to pre-
dict the in vivo thyroid-mediated effects in EDSP assays. This was
conﬁrmed by Cox et al. (2014). Whilst the ToxCast™ thyroid assays
comprised thyroid hormone receptor binding and transcriptional
activation assays, it was determined that binding to the thyroid
hormone receptor was not the MoA arising from altered clearance
of thyroid hormones. Although ToxCast™ includes assays that
measure enzymatic activity relevant to thyroid hormone clearance,
Rotroff et al. (2013), concluded there was a lack of speciﬁcity for
thyroid-active chemicals in these ToxCast™ assays. A number of
targets exist where chemicals may interact to interfere with thy-
roid hormone signaling. This can be at the level of central regula-
tion in the hypothalamus, at the pituitary gland, the thyroid
gland itself or in peripheral tissues such as the liver that affects
thyroid hormone clearance (Murk et al., 2013). Thus, an AOP for
thyroid-mediated effects would beneﬁt from the development of
new in vitro methods to replace the current animal test systems
in use which measure the effects of chemicals upon thyroid
hormone clearance.
Fig. 3. Illustration of a possible progression along an integrated approach to testing
and assessment (IATA).
G. Patlewicz et al. / Regulatory Toxicology and Pharmacology 71 (2015) 463–477 471Another example is that of the AOP for skin sensitisation and
the fact that the typical assay presently advocated to characterize
the MIE is the DRPA. This assay has several shortcomings which
limit its scope for potency prediction (Roberts and Patlewicz,
2014). Whilst the DRPA detects inherent reactivity, it does not
provide any information on the kinetics such as a relative rate con-
stant (Roberts et al., 2008). A modiﬁcation could be made to the
protocol as demonstrated in Roberts and Natsch (2009) which
would address this speciﬁc limitation. Peptide depletion values
cannot be derived with sufﬁcient accuracy for substances with lim-
ited solubility in the solvents as prescribed by the DPRA protocol,
hence substances that are too hydrophobic cannot be adequately
measured. The DRPA also has no metabolic competence. It needs
to be coupled with other test or non-testing approaches to identify
the potential biological transformations as a result of oxidation or
other enzymatic processes. Using the SCF to evaluate the assay and
identify its scope and limitations is critical in ensuring its valid use
and in proposing reﬁnements, all of which can ultimately be used
to update the corresponding AOP.
The Sustained AHR activation liver tumor promotion AOP also
reveals test method reﬁnement and development needs. For
example, how can in vitro test methods represent the Area-Un-
der-the-Curve phenomenon for differentiating between an initial
molecular event and the MIE for AHR-induced rodent liver tumor
promotion? How can test methods be designed to represent the
complicated interactions of multiple cells types locked into the
precise zonal geometry of the hepatic lobule (Andersen et al.,
1997; Chang et al., 2005; Sheikh-Bahaei et al., 2010)? Since
2,3,7,8-tetrachlorordibenzo-p-dioxin-induced (TCDD-induced)
AHR activation gives rise to both hepatocellular and cholangiolar
tumors, stem cell differentiation and proliferation responses
appear to play a central role in this AOP. Therefore, one could pro-
pose that HT/HC hepatocellular stem cell methods are a needed
tool to further examine this AOP. How can test methods be devel-
oped to predict the complex histopathology that is necessary for
AHR-induced liver tumor promotion (Goodman and Sauer, 1992;
Hailey et al., 2005)? For instance, are there hepatic cells lines that
mirror the glutathione S-transferase (GSTP+) focal cells that appear
to be the target for AHR-induced promotion and are there
pathways involving apoptosis that explain how these cells escape
programmed cell death? Recently, evidence involving inﬂamma-
tion obtained with (Tumor necrosis factor alpha) TNFa knockout
mouse model has shown the importance of inﬂammatory cytoki-
nes in driving the mouse liver tumor response to TCDD (Pande
et al., 2005; Kennedy et al., 2014). How could HT methods be
designed to examine the important role of inﬂammatory cytokines
in liver tumor promotion? Will genomic pathways and networks
be identiﬁed with the AHR liver tumor promotion key events that
can enable HT in vitro results to be used to predict an AHR ligand’s
liver tumor potential? Currently, a number of research efforts to
identify genomic signatures predictive of liver tumor potential
have been published but the recommended genomic patterns do
not align with gene changes that have been reported for the AHR
(Heise et al., 2012; Fielden et al., 2008; Fletcher et al., 2005;
Boutros et al., 2011; Vezin et al., 2004). Until clear genomic signals
with pathways clearly linked to the key events required for AHR-
mediated liver tumor promotion are established, for both
parenchymal and non-parachymal cells, the current collection of
genomic responses are not suitable for prediction (hazard) but
could be used to establish dose–response relationships for biologi-
cal activity and possible risk assessment.
3.4. Integrated approaches to testing and assessment
Integrated approaches to testing and assessment (IATA) are
pragmatic approaches which exploit existing information (includ-ing human data and exposure information), alternative approaches
(such as in chemico, in vitro including HT/HC screening assays), and
tailored testing strategies. Ideally future IATA will rely on results
from appropriate combinations of non-testing approaches, in
chemico, in vitro tests that target key events, along with an AOP
that could provide sufﬁcient information for hazard and risk
assessment purposes (Fig. 3).
Fig. 3 highlights the interplay between gathering all existing
information and structuring what additional information might
need to be generated to address a speciﬁc regulatory purpose for
a given chemical or group of chemicals. Indeed, this idea to consid-
er exposure information along with measures of toxicity in the ini-
tial stages of a risk assessment was articulated in the HESI RISK 21
roadmap, which can be easily illustrated through a Matrix tool
designed to identify exposure and toxicity data gaps and determine
the most appropriate studies to address them (Pastoor et al., 2014).
For IATA, the type and extent of data generated would focus on one
or more key events. The number of key events and their associated
test systems will drive the development of testing strategies to
facilitate the collection and interpretation of test outcomes. IATA
have been in widespread use for some time; indeed REACH articu-
lates endpoint-speciﬁc integrated testing strategies (ITS) in its
technical guidance for its information requirements (ECHA,
2008). Aligning IATA with AOPs represents a step change in terms
of IATA development in that it ensures speciﬁc testing is directed
to what is most relevant for the decision in mind, for the chemi-
cal(s) of interest, and which would be readily interpretable from
the biological context.
The complexity of an IATA will depend on the completeness of
an AOP, the decision context, and the chemical(s) under consid-
eration. Again the SCF guides the utility of an AOP for this purpose
by evaluating the assays underpinning the KEs and their prediction
models, and determining what combination of assays or non-test-
ing approaches lend themselves to IATA development and for what
type of regulatory decision. The role AOPs play in informing the
development of IATA for different regulatory purposes was dis-
cussed in detail at the Workshop entitled ‘‘Advancing AOPs for
Integrated Toxicology and Regulatory Applications’’ in March
2014 and the insights were summarized in Tollefsen et al. (2014).3.4.1. Case study 2; skin sensitisation AOP as applied to IATA
There have been several efforts to consider how to combine in
silico, in chemico, in vitro, and in vivo data together as part of an
IATA to make an assessment of skin sensitisation potential based
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development of IATA for hazard identiﬁcation and to a lesser
extent for potency. The results of 2 in chemico assays and 1 in vitro
test characterizing the MIE, KE2, and KE3 (as described in Table 4)
were collected for 145 chemicals and compared with the corre-
sponding results from the LLNA (Natsch et al., 2013). A Bayesian
network analysis was derived to predict skin sensitisation potency
(in terms of strong, moderate, weak categorizations) for various
classes of sensitisers (Jaworska et al., 2011, 2013). Other testing
strategies have also been proposed including that of Bauch et al.
(2012), Buist et al. (2013), Rorije et al. (2013), Tluczkiewicz et al.
(2013) and Nukada et al. (2013) though not all of these have been
framed them in the context of AOPs. An IATA could in principle
solely focus on non-testing approaches such as QSARs before
deciding on what additional data would be warranted to generate
to address a speciﬁc purpose.
The AOP for skin sensitisation has been implemented in the
OECD Toolbox to facilitate the formation of chemical categories
and associated read-across using the knowledge and data for the
different key events (OECD, 2014b). This implementation could
be likened to a type of IATA that focuses solely on existing data
and other non-testing approaches and marks a step change in
terms of how read-across and other QSAR information can be
applied and will be developed in the future. In the Toolbox, a set
of proﬁlers have been developed which encode available knowl-
edge derived for substances that had been tested in assays that
characterize each of the key events. These proﬁlers are not direct
predictors of the key events or the adverse outcome but provide
a mechanistic basis for grouping chemicals together. The Toolbox
contains traditional proﬁlers which encode known SAR informa-
tion for chemicals tested in in vivo methods such as the LLNA
and GPMT as well as hypothetical SARs based on organic chemistry
reaction principles (Aptula and Roberts, 2006). These speciﬁc pro-
ﬁlers are called the Protein Binding alerts by OASIS and OECD.
There are also proﬁlers for lysine and cysteine depletion based
on data generated on chemicals tested in the DRPA as well as pro-
ﬁlers for chemicals tested in the KeratinoSens™ assay (Emter et al.,
2010), the human cell line activation test (h-CLAT) (Sakaguchi
et al., 2007), and myeloid U937 skin sensitisation test (MUSST)
(Python et al., 2007). A user starts by proﬁling their chemicals on
the basis of protein binding alerts. If alerts are identiﬁed, then a
stepwise approach of gathering data for each of the different
events and investigating the feasibility of deriving a read-across
prediction is evaluated. Speciﬁc thresholds to pass from one key
event to the next have been encoded into the AOP implementa-
tion to help in the interpretation of the novel data. Depending
on the decision being made and the availability of experimental
data for the related analogues at each step of the IATA and the
chemical of interest, sufﬁcient scientiﬁc conﬁdence could be
potentially be reached at the molecular initiating event, or alter-
natively other key events may need to be considered in the
evaluation.
A complementary implementation of the skin sensitisation AOP
was proposed by Patlewicz et al. (2014c) through the development
of a non-testing IATA which relies on a combination of existing
information on the physical form of the substance itself (i.e.,
whether it is a gas, liquid or solid), available experimental data
for skin sensitisation, skin corrosion, and mutagenicity data as
extracted from the OECD Toolbox in addition to proﬁlers for
reactivity, as well as components for the expert system Tissue
Metabolism Simulator (TIMES) (Patlewicz et al., 2014b) to predict
the same endpoints. The underlying basis of this IATA is to consider
what inherent data might exist for the substance of interest that
would inform its skin sensitisation potential and to establish
whether any sensitisation testing would be justiﬁed e.g., the sub-
stance is a gas or is corrosive.3.4.2. Case study 3; AHR AOP as applied to IATA
The AHR case study (as detailed in Table 6) provides an exten-
sive dataset for the purposes of outlining how one can frame an
IATA. A decision tree approach, summarized in brief in Fig. 4, is
proposed to outline what additional, more complex, testing could
be considered when a substance has the potential to be an AHR
ligand that could result in rat liver tumors. The IATA decision tree
(Fig. 4) integrates consideration of exposure into the decision mak-
ing. Previously (Becker et al., 2015), we discussed application of the
exposure:activity ratio concept at the latter stages of this decision
tree. In this evolved IATA, we propose, that in addition to evaluat-
ing activities in assays, exposure activity proﬁling can help to place
such results of early molecular events and cellular responses into
the context of existing human exposures. Since sustained AHR acti-
vation is the MIE, care will need to be exercised in interpreting
exposure activity proﬁling based on assays that are not measures
of sustained activation.
This proposed AHR decision tree (Fig. 4) does not include testing
in human parenchymal and non-parenchymal cells although this
possibility could be considered to see if differences in response
between rats and humans, e.g., transcriptional changes, response
to apoptotic stimuli, and differentiation and proliferation, are so
different as to call into question the human relevance for a ligand
inducing AHR binding or activation.
Again the completeness of a given AOP facilitates the extent to
which an IATA can be developed, how encompassing it will be in
terms of whether it can be used for hazard identiﬁcation or only
for prioritization or chemical categorization purposes. The two
AOPs cited here have been extensively delineated to permit
detailed IATA to be developed that can be applied for hazard iden-
tiﬁcation decisions and beyond.
3.5. Hazard and risk assessment
Identiﬁcation of an adverse outcome is a necessary element for
both hazard identiﬁcation and risk assessment. The use of AOPs for
hazard identiﬁcation and risk assessment, therefore will require a
focus on the performance of analytical methods and prediction
models at each key event and key event relationship within the
AOP. In the utilization step, one will need to document the scien-
tiﬁc support, based on the WoE, for using one or more of the key
events and key event relationships to predict the adverse outcome.
As a general rule, the more ‘downstream’ a key event is towards
the adverse outcome, the greater the conﬁdence that the relevant
key event relationship could be used to predict the adverse out-
come. Conversely, the more ‘upstream’ a key event is from the
adverse outcome, the less conﬁdence in the use of its associated
key event relationship to predict the adverse outcome.
Considerable research over the last 15 years has focused on
developing and applying methods to use knowledge of MoA to
inform human health hazard and risk assessments (Meek et al.,
2014a,b). Typically, when applying a MoA to characterize human
hazard or risk, one needs to understand not only the molecular
initiating event and adverse outcome, but also critical key events
further along the pathway. One also needs to understand dose–
response and temporal concordance of key events. When data
are available from a molecular initiating event, and yet knowledge
of the intermediate key events is not available, conﬁdence would
generally be lacking, and results measuring the molecular initiat-
ing event (or other early key events) would be judged insufﬁcient
to allow a conclusion to be made regarding the likelihood that an
adverse outcome would occur. This arises because we do not gen-
erally have sufﬁcient knowledge of the biology and complex biolo-
gical interactions and dose–response and time courses to link all of
the key events in an AOP together quantitatively. For example, one
of the main challenges in using any AOP stems from the fact that in
Fig. 4. Decision tree approach to guide testing for a substance with the potential to be an AHR ligand which results in rat liver tumor promotion. (See above-mentioned
references for further information.)
2 Risk factors are derived on the basis of odds ratios analysis and represent a ﬂag for
a concern whereas predictors would imply an actual estimate of the AO.
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of events, some of which may not be known and some may not
be reﬂected in acute and sub-acute biological responses conducive
to HT/HC approaches. Thus, for many AOPs at the present time,
when data are limited to measurements of the molecular initiating
event or early key events, current information will not allow
conclusions to be drawn regarding potential hazard or risk. How-
ever, for some AOPs, where extensive downstream key events are
available, coupled to robust pharmacokinetic and exposure
information, hazard and risk can be more readily deﬁned. The
AHR AOP is a good example. Quantitative modeling of the liver
tumor promotion response is made possible by extensive
dosimetry data. These quantitative data include AHR-binding,
AHR-induced transcriptional responses, rat liver initiation-
promotion results, and interim and terminal NTP cancer bioassay
results (Budinsky et al., 2014; Hailey et al., 2005; Conolly and
Andersen, 1997; Moolgavkar et al., 1996; Simon et al., 2009).
Whilst the relevance of the rodent liver tumor response to humans
remains in doubt, the quantitative aspects of this AOP provide an
example of how key event relationships can be understood on a
quantitative basis (see Lorber et al., 2009). It is perhaps worth
nothing that persistent AHR ligands produce rodent liver tumors
provided that high levels of AHR activation are sustained. In
contrast, humans develop chloracne with clinical onset occurring
in short order following fairly high levels of AHR activation.
Consequently, chloracne may offer a non-controversial human
endpoint for risk assessment that can beneﬁt from closer temporal
linkage between gene changes in keratinocytes and sebocytes that
culminate in the apical outcome.
It may be possible to develop AOP hazard prediction models
from a combination of assays characterizing early key events inthe AOP. These may include QSAR and/or predictions based on che-
mical knowledge, in chemico, in vitro assays, possibly using hetero-
logous expression systems and, in some cases, short term in vivo
assays. An example is provided by recent work using the ToxCast™
dataset from US EPA and almost 100 statistical tests of association
to predict 60 in vivo endpoints—the relationships between assay
results and adverse outcomes could be interpreted such that the
assay results were risk factors2 but not predictors (Thomas et al.,
2012). As more AOPs are developed, prediction models will likely
improve. Before any AOP is used for either screening purposes or
hazard prediction, additional work will be needed to develop and
evaluate the associated prediction model, an example where such
an exercise was undertaken can be found in Cox et al. (2014).
Lessons learned from the use of well-established MoAs in haz-
ard identiﬁcation and risk assessment can be applied to AOPs.
Recently the HESI RISK21 project investigated enhancements to
the existing mode of action/human relevance framework and key
events (KE)/dose–response Framework to make the best use of
quantitative dose–response and timing information for key events
as part of an effort to advance the next-generation of chemical risk
assessments. The resulting quantitative KE/dose–response frame-
work (QKEDRF) provides a structured quantitative approach for
systematic examination of the dose–response and timing of key
events resulting from a dose of a bioactive agent that causes a
potential adverse outcome (Simon et al., 2014). With its focus of
quantitative dose–response, the QKEDRF approach provides a
means for quantiﬁcation of key event relationships. At this time,
3 The choice of the target value of an EAR is a regulatory decision. If the exposure
concentration of a chemical is 10,000 fold lower than the activity level of that
chemical, very little concern is warranted. If the exposure and activity are equal
resulting in an EAR of 1, perhaps greater concern is appropriate. To contextualize EAR
values, Becker et al. (2014b) compared EARs for chemicals with estrogenic activity to
the EAR for genistein, a common phytoestrogen that is part of a healthy diet. The ratio
between the EAR for a chemical and the EAR for genistein is called the Relative
Estrogenic Exposure Activity Quotient (REEAQ). The use of REEAQs contextualizes the
EAR value in terms of a ubiquitous estrogenic exposure, that of genistein.
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development and examples using these approaches and the
QKEDRF is mentioned for completeness.
3.6. Considerations for dosimetry
Scholz et al. (2013) indicate that ‘‘most if not all types of toxicity
can be explained by an initial molecular interaction.’’ However,
untilmore experience is gainedwith developing and applying AOPs,
this claim remains a testable hypothesis. Thomas et al. (2013)
recently proposed a tiered evaluation framework that comprises
three tiers. Tier 1 utilizes an in vitro HTS battery, such as ToxCast™
and Tox21, to evaluate activity of substances in biologically relevant
assays, and then links these to exposure to enable a margin of
exposure (MOE) determination. If the MOE is adequate, no further
evaluation would be needed. For substances with lower MOEs, Tier
2 would entail in vivo evaluation of transcriptomics coupled to an
MOE determination. Again, after Tier 2, substances with an
adequate MOE would proceed no further, but substances with
lowerMOEs would proceed to Tier 3. Tier 3 consists of conventional
animal toxicity tests, but which may be tailored based on
knowledge gained from the preceding mechanistic in vitro and
in vivo studies. Tier 3 is also coupled with a MOE evaluation.
This framework did not speciﬁcally incorporate AOPs, at the
time of its development though this could be a consideration
now. For example, in Tier 1, the Thomas et al. (2013) framework
incorporates evaluation streams for chemicals that act via ‘‘speciﬁc
MoAs’’ and those that act via ‘‘non-speciﬁc MoAs.’’ For substances
identiﬁed in Tier 1 as acting by ‘‘speciﬁc MoAs’’, the biological pro-
ﬁle determined could be compared to initial molecular events or
key events for a suite of AOPs. Following such a matching exercise,
one will then have a set of AOPs that could be further evaluated.
This may obviate the need for Tier 2 or Tier 3 evaluations, provided
there is sufﬁcient scientiﬁc conﬁdence for the use of the AOP. Alter-
natively the AOP can be used along the lines of an IATA to tailor
Tier 2 or Tier 3 evaluations.
In general, for non-selective chemicals, consideration of
dosimetry is vital to development of an AOP whereas for selective
chemicals, the issues of potency and efﬁcacy will likely be more
important. However, the dosimetry for some chemicals that act
via a selective mechanism in vitro remains necessary for under-
standing in vivo results and for AOP development (Hengstler
et al., 2011; Teeguarden et al., 2011, 2013; Teeguarden and
Hanson-Drury, 2013).
The prediction of concentrations measured in human body ﬂu-
ids from known administered doses of a chemical is a necessary
part of the application of AOPs. Results from HT/HC or other in vitro
assays need to be contextualized in terms of human exposures
(Becker et al., 2014b,c; Wetmore et al., 2011). In fact, as will be
seen, the incorporation of exposure is often critical for increasing
the predictive power of models (Morgan et al., 2013).
In vitro assays produce an estimate of a concentration needed to
produce an effect in the test system. The exposure:activity ratio
(EAR) has been developed for this purpose (Becker et al.,
2014a,b,c). Values for exposure and activity may be expressed as
oral doses, urinary concentrations or steady state blood or plasma
concentrations. For comparison, both values must be expressed in
the same way. For example, if one wishes to compare the results of
estrogenic screening assays with urinary excretion data from
NHANES, then the assay result needs to be expressed as a urinary
concentration using in vitro-to-in vivo extrapolation (IVIVE)
(Aylward et al., 2011; Aylward and Hays, 2011; Becker et al.,
2014b,c; Wetmore et al., 2011).
In its ﬁrst use, the EAR compared human urinary concentrations
measured in NHANES to human urinary biomonitoring equivalents
(Becker et al., 2014a). The EAR is also used to compare effectconcentrations from in vitro assays to steady state blood concen-
trations estimated from human urinary data with IVIVE (Becker
et al., 2014a, Becker et al., 2014b; Wetmore et al., 2011).
Hence, one can think of the EAR as the environmentally relevant
human exposure level divided by combined result from the rele-
vant in vitro assays. If the EAR is well above the target value, indi-
cating that exposure is low relative to the activity of the chemical
and there is sufﬁcient conﬁdence in the dosimetry model, then the
EAR can be documented and published. Doing so will establish a
degree of conﬁdence that current human exposures will not lead
to the adverse outcome within the population3.
The next step would be to reﬁne the dosimetry model. For
example, Wetmore et al. (2011) used a generic model that account-
ed for plasma protein binding, phase I and phase II metabolism,
bioavailability, and red blood cell partitioning. This model, albeit
generic, was more sophisticated than those used in earlier
attempts at IVIVE (Rotroff et al., 2010). The use of the initial EAR
for screening depends on the level of conﬁdence. Reﬁnement of
the dosimetry model may require laboratory experimentation
and possibly the use of animals. Consequently, the experiments
need to be well designed and narrowly targeted toward obtaining
speciﬁc results. Finally, the results of and conﬁdence in the reﬁned
EAR will determine whether additional testing, possibly in vivo
testing in animals, should be contemplated.
In summary, the most useful piece of information for applying
an AOP in a risk assessment context would be a qualitative
relationship between the dose–response of the molecular initiating
event and the dose–response of the adverse outcome. However, if
sufﬁciently robust dose–response data exist for a molecular initiat-
ing event and/or other key events, this can be used to determine
the most appropriate dose–response model for an adverse out-
come in a risk assessment (Simon et al., 2014). A relationship
expressed using quantitative dose–response enables the consid-
eration of exposure information with relative ease. The next most
powerful piece could be provided by a strong correlation between
a measure of the molecular initiating event and the adverse out-
come. Patlewicz et al. (2013a) provide a general approach for
evaluation of prediction models based on their expected use.
4. Summary
The AOP framework provides an overarching basis for contextu-
alizing in vitro methods and their prediction models in a manner
that can be interpreted for regulatory decision making. Currently
there is a strong motivation at least by the OECD to develop AOPs
that could be applied in one of three main avenues – informing test
methods, enhancing read-across, or helping to develop IATA. Ulti-
mately these AOPs and the approaches they anchor will be used
to address regulatory questions such as prioritization, hazard iden-
tiﬁcation, and risk assessment. Whilst there has been signiﬁcant
momentum to develop AOPs and start to populate an AOP Wiki
repository, there has been little focus on the ultimate application
of AOPs in these different regulatory applications. A harmonized
framework approach to establish scientiﬁc conﬁdence is critical
to bolster scientiﬁc rigor, improve communication and under-
standing of the scientiﬁc justiﬁcation for speciﬁc applications,
and enhance uptake and use of Tox21 approaches by regulatory
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need to be agreed upon and utilized to ensure robust and transpar-
ent review and determination of ﬁt-for-purpose uses of AOPs for
regulatory acceptance and use.
Here a scientiﬁc conﬁdence framework previously described in
Cox et al. (2014) has been adapted and extended for AOPs. The
SCF comprises 3 core elements – analytical validation of the assays
characterizing key eventswithin the AOP, qualiﬁcation of prediction
models derived from these assays and utilization of AOP based pre-
diction models for speciﬁc purposes; the latter being anchored
closely with the evolved Bradford Hill considerations, in which each
key events and key event relationships in an AOP are evaluated and
scored as part of a WoE determination. The SCF has been illustrated
with respect to a handful of example AOPs to demonstrate how the
practical application of an AOP strongly depends both on its com-
pleteness and the decision context in mind. The example AOPs are
different in character and in their level of maturity. The AOP for
estrogen activity lends itself to prioritization purposes through
the use of assays thatmeasure early key events speciﬁcally estrogen
binding and transactivation assays. A semi quantitative but com-
plete AOP for skin sensitisation can be and is used in many types
of applications such as chemical categorization and read-across, as
well as IATA for hazard assessment purposes. A number of IATA
have been developed and the AOP itself has also been incorporated
into the OECD Toolbox to support read-across. Applications of the
AHR AOP are complicated by the lack of concrete assays to measure
the molecular initiating event. The only means to currently predict
an AHR ligands ability to act as a rodent liver tumor promoter is to
test the ligand in a sub-chronic or chronic assay that pays careful
attention to the classic histological changes (e.g., hepatopathy) that
are required for tumor promotion to ensue (Hailey et al., 2005).
As such it’s predominant value is to develop an IATA for hazard
and risk assessment purposes. The role of AOPs in hazard and
risk assessment have also been discussed in light of exposure
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